免疫检查点抑制剂致腹泻/结肠炎后免疫治疗再挑战的思考  

Considerations on rechallenging immunotherapy after immune checkpoint inhibitors-induced diarrhea and colitis

作　　者：赵健蓉 陈济[1] Zhao Jianrong;Chen Ji(Department of Oncology,Chengdu Seventh People's Hospital,Chengdu 610041,China)

机构地区：[1]成都市第七人民医院肿瘤科,四川成都610041

出　　处：《实用药物与临床》2025年第4期304-309,共6页Practical Pharmacy and Clinical Remedies

摘　　要：免疫相关性腹泻/结肠炎(Immune-mediated diarrhea and colitis,IMDC)是免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)治疗后的常见不良反应之一。IMDC的发生可能提示患者对免疫治疗有较好的免疫反应,但严重的IMDC也可能对患者的预后产生负面影响。IMDC后是否进行免疫治疗再挑战,一直是临床医生面临的难题。本文就免疫治疗再挑战的安全性、有效性、治疗前评估以及二级预防策略进行了系统性综述,旨在为临床决策提供参考依据。Immune-mediated diarrhea and colitis(IMDC)is one of the common adverse reactions after treatment with immune checkpoint inhibitors(ICIs).The occurrence of IMDC may indicate that patients have a good immune response to immunotherapy.However,severe IMDC may also affect the prognosis of patients.After IMDC,whether to rechallenge immunotherapy has always been a puzzle for clinicians.This paper systematically reviews the safety,efficacy,pre-treatment evaluation and secondary prevention strategy of rechallenging immunotherapy,aiming to provide reference for clinical decision-making.

关 键 词：免疫检查点抑制剂 免疫相关性腹泻/结肠炎 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]